- Home
- TAC vs XENE Comparison
TAC vs XENE Comparison
Compare TAC & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | XENE |
|---|---|---|
| Founded | 1909 | 1996 |
| Country | Canada | Canada |
| Employees | 1350 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | TAC | XENE |
|---|---|---|
| Price | $12.94 | $54.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $23.67 | ★ $67.17 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.24 | $2,436.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.82 | $26.74 |
| 52 Week High | $17.88 | $62.91 |
Technical Indicators
Market Signals| Indicator | TAC | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 58.97 |
| Support Level | $12.08 | $39.93 |
| Resistance Level | $13.94 | $62.91 |
| Average True Range (ATR) | 0.45 | 2.05 |
| MACD | 0.05 | -0.33 |
| Stochastic Oscillator | 76.04 | 20.46 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.